PCSK9 and Cirrhosis: Thus, we postulates that the inhibition of PCSK9 by alirocumab, a monoclonal antibody against PCSK9 [16], can decrease ox-LDL level, attenuate liver fibrosis, and intrahepatic inflammation; then, it consequently ameliorates cirrhosis-related complications.